Defence Therapeutics (TSE:DTC) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Defence Therapeutics Inc. has announced that its AccuTOX® technology not only kills tumors but also boosts the immune system, significantly enhancing the effectiveness of Immune Checkpoint Inhibitors (ICI) in treating solid tumors. AccuTOX® achieves this by converting ‘cold’ tumors, which typically resist ICI treatment, into ‘hot’ tumors that are more vulnerable to immune attack. The company has observed a tenfold increase in treatment efficacy in preclinical studies and sees AccuTOX® as a potential game-changer for increasing the patient population eligible for ICI treatment.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money